Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Sim, Adrian Chong Nyi ^a,b   Too, Chien Tei ^a   Oo, Min Zin ^b   Lai, Junyun ^a   Eio, Michelle Yating ^a   Song, Zhenying ^a   Srinivasan, Nalini ^c   Tan, Diane Ai Lin ^a   Pang, Shyue Wei ^d   Gan, Shu Uin ^a   Lee, Kok Onn ^e   Loh, Thomas Kwok Seng ^e   Chen, Jianzhu ^c   Chan, Soh Ha ^c   Macary, Paul Anthony ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DSO NATIONAL LABORATORIES   (Singapore)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EBV-ENCODED NUCLEAR ANTIGEN 1; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MATRIX PROTEIN; MONOCLONAL ANTIBODY; VIRUS ANTIGEN;

ANIMAL; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOLOGY; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE; VIRUS LATENCY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

EID: 84888171286     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03232     Document Type: Article

References (31)

1. Hislop, A. D., Taylor, G. S., Sauce, D.& Rickinson, A. B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Ann. Review Immunol. 25, 587-617 (2007). (Pubitemid 46697918)
2. Glaser, S. L. et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int. J. Cancer 70, 375-382 (1997). (Pubitemid 27107262)
3. Shanmugaratnam, K.Histological typing of nasopharyngeal carcinoma. IARC Sci. Publ. 20, 3-12 (1978). (Pubitemid 9111584)
4. Fogg, M. H.,Wirth, L. J., Posner, M. & Wang, F. Decreased EBA-1-specific CD81 T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 106, 3318-3323 (2009).
5. Weidanz, J. A., Hawkins, O., Verma, B. & Hildebrand, W. H. TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells. Int. Rev. Immunol. 30, 328-340 (2011).
6. Yewdell, J.W. DRiPs solidfy: progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 32, 548-558 (2011).
7. Held, G. et al.Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 34, 2919-2929 (2004). (Pubitemid 39430167)
8. Sastry, K. S. et al. Targeting hepatitis B virus-infected cells with a T-cell receptorlike antibody. J. Virol. 85, 1935-1942 (2011).
9. Chen, M. R. et al. The major immunogenic epitopes of Epstein-Barr virus (EBV) nuclear antigen 1 are encoded by sequence domains which vary among nasopharyngeal carcinoma biopsies and EBV-associated cell lines. J. Gen. Virol. 80, 447-455 (1999).
10. Edwards, R. H., Seillier-Moiseiwitsch, F. & Raab-Traub, N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 261, 79-95 (1999). (Pubitemid 29395060)
11. Lee, S. P., Tierney, R. J., Thomas, W. A., Brooks, J. M. & Rickinson, A. B. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J. Immunol. 158, 3325-3334 (1997). (Pubitemid 127484050)
12. Young, L. S. et al. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol 68, 2853-2862 (1987).
13. Cheung, S. T. et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 83, 121-126 (1999). (Pubitemid 29409487)
14. Yajima, M. et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cellmediated and humoral immune responses. J. Infect. Dis. 198, 673-682 (2008).
15. Hawkins, O. E. et al. Identification of breast cancer peptide epitopes presented by HLA-A0201. J. Proteome Res. 7, 1445-1457 (2008).
16. Makler, O., Oved, K., Netzer, N.,Wolf, D. & Reiter, Y. Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity. Eur. J. Immunol. 40, 1552-1565 (2010).
17. Jain, R., Rawat, A., Verma, B., Markiewski, M. M. & Weidanz, J. A. Antitumor actitivty of a monoclonal antibody targeting major histocompatibility complex class I-her2 peptide complexes. J. Natl. Cancer Inst. 105, 202-218 (2013).
18. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. & Germanin, R. N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using monoclonal antibody. Immunity 6, 715-726 (1997). (Pubitemid 27305734)
19. Denkberg, G., Lev, A., Eisenbach, L., Benhar, I. & Reiter, Y. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward amelanoma differentiation antigen. J. Immunol. 171, 2197-2207 (2003). (Pubitemid 37025524)
20. Rubin, B., Malissen, B., Jorgensen, P. N. & Zeuthen, J. Recognition of insulin on MHC-class-II-expressing L929 cells by antibody and T cells. Res. Immunol. 140, 67-74 (1989). (Pubitemid 19121899)
21. Tamminen,W. L., Wraith, D. & Barber, B. H. Searching for MHC-restricted antiviral antibodies: antibodies recognizing the nucleoprotein of influenza virus dominante the serological response of C57BL/6 mice to syngeneic influenzainfected cells. Eur. J. Immunol. 17, 999-1006 (1987). (Pubitemid 17101315)
22. Bihl, F. et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J. Immunol. 176, 4094-4101 (2006). (Pubitemid 44264388)
23. Levitskaya, J. et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688 (1995).
24. Blake, N., Haigh, T., Shaka'a, G., Croom-Carter, D. & Rickinson, A. The importance of exogenous antigen in priming the human CD81 T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165, 7078-7087 (2000). (Pubitemid 32001182)
25. Catalina, M. D., Sullivan, J. L., Bak, K. R. & Luzuriaga, K. Differential evolution and stability of epitope specific CD8(1) T cell responses in EBV infection. J. Immunol. 16, 4450-4457 (2001). (Pubitemid 32954322)
26. Stuber, G. et al. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int. Immunol. 7, 653-663 (1995).
27. La Gruta, N. L. et al. A virus-specific CD81 T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc. Natl. Acad. Sci. U. S. A. 103, 994-999 (2006). (Pubitemid 43212210)
28. Gottschalk, R. A. et al. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc. Natl. Acad. Sci. U. S. A. 109, 881-886 (2012).
29. Engels, B. et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23, 516-526 (2013).
30. Ryan, J. L. et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffinembedded tissue and plasma. J. Mol. Diag. 6, 378-385 (2004). (Pubitemid 39517407)
31. Parham, P. & Brodsky, F. M. Partial purification and some properties of BB7.2 a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3, 277-299 (1981). (Pubitemid 12144723)